Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the
Company will report second quarter 2009 financial results following the
close of the U.S. financial markets on Monday, August 10, 2009.
The Company will host a conference call at 5:00 p.m. ET, on Monday,
August 10, 2009. Interested parties can access the conference call by
way of web cast or telephone. The live web cast will be available at www.salix.com.
A replay of the web cast will be available at the same location. The
telephone numbers to access the live conference call are (888) 510-1783
(U.S. and Canada) or (719) 457-2621 (international.) The telephone
numbers to access the replay of the call are (888) 203-1112 (U.S. and
Canada) or (719) 457-0820 (international). The access code for the
replay is 5354538.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina,
develops and markets prescription pharmaceutical products for the
treatment of gastrointestinal diseases. Salix’s strategy is to
in-license late-stage or marketed proprietary therapeutic drugs,
complete any required development and regulatory submission of these
products, and market them through the Company’s gastroenterology
specialty sales and marketing team.
Salix markets XIFAXAN® (rifaximin) tablets 200 mg, OSMOPREP®
(sodium phosphate monobasic monohydrate, USP and sodium phosphate
dibasic anhydrous, USP) Tablets, MOVIPREP® (PEG 3350, Sodium
Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and
Ascorbic Acid for Oral Solution), VISICOL® (sodium phosphate
monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Tablets, APRISO™ (mesalamine) extended-release capsules 0.375 g., PEPCID®
(famotidine) for Oral Suspension, Oral Suspension DIURIL® (Chlorothiazide),
AZASAN® Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC®
2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg
Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream
(Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository
(Hydrocortisone Acetate Rectal Suppositories) 30 mg. METOZOLV™ ODT
(metoclopramide), crofelemer, budesonide foam and rifaximin for
additional indications are under development.
For full prescribing information on Salix products, please visit www.salix.com
or contact the Company at 919 862-1000.
Salix trades on the NASDAQ Global Select Market under the ticker symbol
“SLXP.”
For more information please visit our web site at www.salix.com
. Information on our web site is not incorporated in our SEC filings.
Salix Pharmaceuticals, Ltd.
Adam C. Derbyshire, Executive Vice
President
and Chief Financial Officer or
G. Michael Freeman,
Associate Vice President, Investor Relations and
Corporate
Communications, 919-862-1000
